{"ticker": {"uuid": "b60fdf0a-3072-4ada-ad9b-674277bdd94a", "symbol": "GNLX", "name": "Genelux Corporation Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill", "summary": "GENELUX Corp director John W. Smither sold 12,000 shares of common stock in an open-market transaction at a weighted average price of $2.9082 per share. This sale was made to cover estimated taxes related to the vesting of restricted stock units (RSUs). After the transaction, Smi", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-a15774e7f02b.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:32", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi\u2011Vec in Ovarian Cancer", "summary": "Genelux Corporation announced the publication of translational findings from its Phase 1b/2 VIRO-15 trial, demonstrating that Olvi-Vec-primed immunochemotherapy promotes immune activation and chemotherapy sensitization in platinum-resistant/refractory ovarian cancer (PRROC) patie", "url": "https://finance.yahoo.com/healthcare/articles/genelux-announces-publication-translational-analysis-120000339.html", "source_name": "Market source", "published_at": "2026-07-02T03:40:25", "published_display": "02 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Two Wall Street analysts have issued bullish sentiments on healthcare companies Genelux Corp. (GNLX) and Abivax SA Sponsored ADR (ABVX). Chad Messer of Lake Street maintained a Buy rating on Genelux with a $16.00 price target, while Sam Slutsky of LifeSci Capital maintained a Buy", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ABVX-Q/pressreleases/3077748/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T01:40:05", "published_display": "02 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] GENELUX Corp SEC Filing", "summary": "This article announces a Form 144 SEC filing by GENELUX Corp (GNLX) regarding a proposed sale of 12,000 shares of common stock by an insider. The filing indicates these shares, acquired on June 16, 2026, as restricted stock from the Issuer, have an aggregate market value of $34,8", "url": "https://www.stocktitan.net/sec-filings/GNLX/144-genelux-corp-sec-filing-69dd7523fe31.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:14", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX Corp SEC Filing (Jul 1, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWWlZR1VGNEJLWTExZ0F6YVdYNlotM0FXWklqTGZXTXZXMDRHQzh6MWl5dFJGWXNnZFBvTHZDMUdUYWdvQ2h6cW9hQlNrbm5zQWdHeXRGeWhKOF92aUJRd0NpVm1tRDN3ajA1dHgwcUJUMVVXY1JRQ29JUTBhbXRFbTl0WVRPX3ZwMG1EV0VvNmlvQ0U?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer", "summary": "Genelux announced the publication of translational and clinical findings from its Phase 1b/2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer. The data indicate that Olvi-Vec modulates the tumor microenvironment, activates immune", "url": "https://www.stocktitan.net/news/GNLX/genelux-announces-publication-of-translational-analysis-supporting-aq19b3oa1umr.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:00:25", "published_display": "30 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp. Actuals & Estimates (NASDAQ:GNLX)", "summary": "This article provides an analysis of Genelux Corporation (NASDAQ: GNLX) stock, covering its current price, historical performance, analyst forecasts, and key financial metrics. It includes details on revenue, earnings, market capitalization, and volatility, as well as upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-GNLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:27", "published_display": "26 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Genelux Corp (GNLX), noting its current valuation score is 6.10, ranking it in the lower range within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.40, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T22:10:42", "published_display": "24 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Genelux Corp (GNLX), detailing its current risk score of 1.61, which ranks 281 out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.54 suggests it tends to underperform during market uptrends but experien", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T10:10:16", "published_display": "24 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com", "summary": "Genelux Corporation held its 2026 Annual Meeting of Stockholders, where shareholders elected John Smither as a Class I Director and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting saw", "url": "https://ng.investing.com/news/stock-market-news/genelux-elects-director-and-ratifies-auditor-at-annual-shareholder-meeting-93CH-2568873", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T22:10:56", "published_display": "22 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Genelux Corp For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing announcement for Genelux Corp, specifically an 8K form filed for June 22. It is a brief notice and does not contain detailed financial information but indicates a significant event or disclosure by the company. The article al", "url": "https://za.investing.com/news/stock-market-news/form-8k-genelux-corp-for-22-june-93CH-4338693", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T21:10:55", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) 2026 meeting backs director John Smither and auditor", "summary": "Genelux Corporation held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders elected John Smither as a Class I director to serve until the 2029 Annual Meeting. They also ratified Weinberg & Company, P.A. as the independent registered public accounting fir", "url": "https://www.stocktitan.net/sec-filings/GNLX/8-k-genelux-corp-reports-material-event-7661c33273b0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:57", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Institutional Confidence", "summary": "Genelux Corp (GNLX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 14.81% quarter-over-quarter, reaching 30.96%. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Genelux Corp (GNLX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. As of June 18, 2026, GNLX trades between a resistance of $3.20 and a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/technical", "source_name": "TradingKey", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant", "summary": "GENELUX Corp's Chief Scientific Officer, Yu Yong, received an equity award of 119,318 restricted stock units (RSUs) at no cash cost under the company\u2019s 2022 Equity Incentive Plan. This grant increases his equivalent common stock position to 269,024 shares, with vesting staggered ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-80a86da56b1a.html", "source_name": "Stock Titan", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) director receives RSUs and stock options in new grant", "summary": "Genelux Corp director Mary Mirabelli was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares of common stock at an exercise price of $3.03. These equity awards increase her direct holdings to 102,693 common shares. Both the RSUs and options vest upon ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-5091bc6a677f.html", "source_name": "Stock Titan", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) director receives RSU and stock option grants", "summary": "Genelux (GNLX) director Thomas John was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares with an exercise price of $3.03. These equity awards, not open-market trades, were granted on June 16, 2026, and will vest on the earlier of one year from the ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-a8247091c6a5.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan", "summary": "GENELUX Corp's Chief Technical Officer, Joseph Cappello, has been granted 174,841 restricted stock units (RSUs) under the company\u2019s 2022 Equity Incentive Plan. This grant, awarded at no purchase price, increases his total directly held common stock and RSU holdings to 329,390 sha", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-1e285d25d5f8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan", "summary": "Genelux (NASDAQ: GNLX) has granted its President and CEO, Thomas Zindrick, 730,601 restricted stock units (RSUs) under the company\u2019s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant date, with the remainde", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-4b165b623adf.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants", "summary": "GENELUX (NASDAQ: GNLX) director James L. Tyree was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares at an exercise price of $3.03. Following these grants, Tyree directly holds 96,483 shares of common stock. Both the RSUs and options will vest on th", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-d38b711e91a7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen", "summary": "Genelux Corp (NASDAQ: GNLX) has granted 233,957 restricted stock units (RSUs) to its General Counsel, Eric Groen, as equity compensation under the company\u2019s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-c3ca697f630c.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMzhSdWo1bjR4UnIxR2UtZFpBRXJUN0pLd1lSX3F5a2d3eU5yUlU5X3Z4djJsRWJDZFdpUTYzaGFvZVZ0S21xRXNWQ3NaWlhtamFtUHd0N0VMNEo0TS1UeFd3M2xxU2pxcUJycGNyQ0wtaWs3dXZEdkJuZ3hESHVGZUpuaDNiUFFkUFM3eWRkeWpBTWk1X3pEMVI2dFdRUURUeWo2M3VQaWM2dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Genelux Corp's (GNLX) dividend and stock split history. It states that Genelux Corp has not distributed any dividends over the past five years and has no recorded stock splits. The financial snapshot shows GNLX's current stock price, market ca", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:14", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Genelux Corp (GNLX), covering business segments, regional revenue, and profit contributions. However, the article states that relevant financial data for these categories have not been disclosed by the compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:14", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Genelux Corp (GNLX) has an earnings forecast score of 8.00, placing it highly within the Biotechnology & Medical Research industry. Analysts have set an average price target of $18.00, with a consensus \"Buy\" rating based on 6 analysts.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:41:04", "published_display": "17 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Genelux Corp (GNLX) from TradingKey, noting a current financial score of 7.05, which ranks it 159 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as stable, but its opera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T06:41:04", "published_display": "17 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com", "summary": "Ralph Smalling, Head of Regulatory at GENELUX Corp, sold 192 shares of company stock worth $562 to cover taxes on restricted stock units. Following the sale, Smalling retains 67,611 shares, and the stock is currently trading at $3.08, significantly below its 52-week high. Investi", "url": "https://m.in.investing.com/news/insider-trading-news/genelux-head-of-regulatory-ralph-smalling-sells-562-in-stock-93CH-5441941?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-05T14:40:41", "published_display": "05 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux head of regulatory Ralph Smalling sells $562 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMHR3MXBVUzRrc3FPT2JxVmZNUi1zUGthcHVDLUdwblNSajQxa1d6UmdCVG5zWFBOMzdyQUtmaG1fMzZocWxMZ2VlUHZhdGhRczhMbjhvX3QtQUE4eHNTVjZBaWhoQWZNRzNyeHQzcHFUallDVVF6Rkp6VFJna21iMC0yM204SlZHR2tySkZ2Z2RGUGlibGRtdnJudHI2NmdtSlQ1aHJhemFjMWxNWklqa2dGYzdZaFowWFp3NTkzOG5qS3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux director Thomas John sold $29,801 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQc3p2b2FqZ0pySXlxb0xhaFpxSFJ2QnFpekpSVG1rWVlBMFdJYmVwMDVDSmFvX1JWLVJweFBscG5LeWZPa29NempZVVNUUGZxWThtc2gwSEdRbkY0clNrNy1CM0IxOGN6RldkOU9kR2tLeGZKbjNJSXZvcEdZMjVSRmo5dmRnLU5PYVdCMHdvRjZyek9HOVg1NFBzQUF3ajVlQ202OGxKM09faUdxNnkwMzVhal8wbHZmbFpTdm5n?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genelux CSO Yu Yong sells $1,798 of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPSEl6V2pmSThmWTZqczg2SzFkSFNTUjRrYVhoQk5hSFlILW1DMEVjOFIwNVFxOVAtTmpGall6dUFSaW4ycFRmdWs5NklVc1BVSEY0RDFEX00xLVFURjFKV2g3bXdJbGt0bVY4X1BQQ1JFcHlpVGgzWFBCQ09RTHQ0Ti1nYjJ5cVdRVWZVSGZYTHlfZy1rVTgzdE1QRmhLZEtVbTRrZGhva2dlOXZvNmFjWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux president and CEO Zindrick Thomas sells $8,225 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNRkhZQ0JtbU5vV3ZPOVBnXzBaWXI5eEs0blJxRXI4MndNUTQ1ZldWdTFnYWxPSUI3U1YzcFFEY01PcmcwR0tjWGlscF9JZXVfQ00taFlTMkl1eTg1a1ZlejZYbl95MWQteUNpZ2kzNHo0VFRWU1I4bGFUMVp3XzRESGhhLVBjTjF6cG5kTmRVUVROWDdiblBHTzFKOFpUSzJPLU5rVWlXOVVxWE0tWncwdDBXU1A2VTE2QXpMNTQ5bXkxbGFh?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux CTO Joseph Cappello sells $1,799 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOTjFITl9Bb1VId1RfZmwwbWVObnZjX0U3c0pHSUJYdzBtNXZmLUF6STlrU2lkRWJGc2N0YXpoU0Q3MWZxOWtyQ1ZxVFluUFFvemdIMldZLUpEQjJZZTAyZVFsWUxFV3BYNEliNGhnXzdLbk5XUTdWSjB1WE1qRWVXZFJhajJMdVVOaHNaNzdXWjFab1BQZU9sRFJ3Z1RTRkxlSG42dlhCUTNtUnEtX0hPRWk1c214Nmx2cGEwaw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPYVBjRlR4bzJVTEZIOG5ZcWJhdFhRdElYQURuVWJqZ1NuWWNxaGhod3A3TTNBNHNHbVZPeS03SWVCYVhWYTU1dkU5djFUUTdWbUtrZVFDLTIxOWd5emhXOVhIaU4xcFJLMHprX1pLeUt6bTktV0x5T3lGel83V0p1LVc4WXNHd25fWWdoMjZkMHpwMHJzMFA4MmQxdW85RDZ6NGpRbWdpSzhLbFV0cVFDR2htbzZPRmN6VUNpRTNQMWYzMlZsRU5KYVd2TWZra1kyQnZfUGNBTlJhMld1eE0yQk40V1ktdXBweWhseWxyLTY0X1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNYlk5WnpEUy1WdDhnWlZ0LUlISTZzVG94cVM5WWNGNU8ycVBLNFpZQlZMYUFlcFpFb3h1NmhCcEJoTEVJT1REYmtsSlJYVGkzQ3NTcWF2a1J0V2plX2pnaUNCd1dlZ1BFaEROOWVscGtERXVOdzA2dDZhV1hpQzJ3QjBYSkxzd2pUak12X1UzTjZiT3kxai1MemhwYkk5dGF6SUVKNUJQS2IxaXVNcUZ2X3ZOR1RFdnVMRGVTd2xQQUpVR3ZtQXNmZ3FxQnowZnhFanZwellrb3hfaVVLeGJacGw5anZUTm9JQlB6dVk0UmJRZERpQlZWMUlaU1dHTVU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corporation Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQNE5uLTBkS3VDeDBuSlpGai1EMTVoUW52UkN2d0pMcnFfMjBXQ3g0NEVjQl96d29TOURwTVpvdjBDQ1Fsdy0wdl9iZmdvcE92VmRmNXVYY2VybVdRM1VaT3M1NFVDWFBPbV82Z0NTZFlfeVpSRUtCbGVlZmdvRWgyVDFiSWVtOVhpQUdYa29CV3lUcVlIekE?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux stock falls after announcing proposed public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOM1RZZ25wNFI2THE0ckRueGtUVEdhWHFScUFhaG01Yk9QOUNIdWQ1M2d6OV9wYl91VjBzeWFhQlJma0QzQzYtNm9ZNW9zVzRVTnBmV2plTDJITkVwbkZoYlduOVlNMy1RWFNJajc1UEtWZWc0MWVubVlSa21nWVpsQWZBem9jMFdkS2pqZXd6em5sWk9HSktMZ2p1QzlQeWFPOWFnRFU0SFJxY0FlX2FvbWI2ZWxjN0RwWmx4aE5tOWI?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux: Oncolytic Virus Player Near Phase 3 Finish Line, But Correction Likely (GNLX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRGZ3QkhBRmg0S0wwZEtvbkZ3bE1UQ21BbWxicWM0RFZOaXF3OFZZQjFxTjlGS3BNN2dBOHF5a2FnbHhkQktqR3Z3Rmh0WlBMNjN3LTZod1ExZGRLczR2OHZqMEloY1MwRGdMUUxtbjRxeUNidUs4X2UxcUhHRHI2dWhzWHVpOXF5TEpkMlVaUFpCSVNDaWtHb1FmeGtJVlpCYV9FUGNPOGduc2JjV0JSaF9OUF94dw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$GNLX stock is down 30% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOamxvNXFKb1g5RmdJd2pXSkhPaXVOYmxjbTFLUWlYbFN2T2xFU1BzSjJweXdGUHlWRjQwdVlVd3ZBZElKejFnQUJRZXEyRmlkUGlrRk9GZnU0b3VXZGRYekM1TWo1c3cwSXBQYVl5OHJWMk9TT1lqSnYtSEdWdUc1VUZUMjFoWXBIMWUxYlg0eGVoLXZFc2RTSlJGWnZMb2hWbXgw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxPQ3B5MlVsTlBhcXdmUVllazV2SWFHTmRudHVNdFY3RUYtR1FTXzNIV1VYODF0bTMyVThkOE1LZC11TGN2dUxBZzRPTDQxUDVDdF9PWW5VUk1rZVJkdXRjbTQ2MU1wa3BtejZ5NUhWY1dQLUZLS3duak1fMzIxcnNwUmc4X3N5Q1JXMFNQY1J0ZVd5aHF4NHVUQkpnNlNUU1VWcVljNjhGbkFicUNyOXktR0lZWkVxT09oU0VQZnZObG5RMkJDWHh4czRrUktNZFNrZVhKWnF1YTZ2ZmVzTG14WG1n?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:24:17+00:00", "published_display": "13 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tenet Healthcare Stock Jumps As Analysts Hold Buy Ratings Into Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxNYzlxZUxqQXJsWHRaUDE4SE1xeXUySXpBalJOamFXdlpnOHdQU25fTVFSdGZlcENQX2tLU2ljMXlvNW8xSnFNcHhsYnhJZURQSWNueTR4cVItWVdxbXFOeDNWYVRfOG9rWGpBNUUwT2lBSHVkcFdMdnhEUzdycnczUms3a3dzSDk5?oc=5", "source_name": "timothysykes.com", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director sells 12,000 shares to cover RSU tax bill", "summary": "GENELUX Corp director John W. Smither sold 12,000 shares of common stock in an open-market transaction at a weighted average price of $2.9082 per share. This sale was made to cover estimated taxes related to the vesting of restricted stock units (RSUs). After the transaction, Smi", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-a15774e7f02b.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:32", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Tenet Healthcare (THC) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTGpMSWYxM2M3RmxZNHFVMm5pTnNfeTZKNzNiWHFJRTBkUDYtMWJaOFB0ZUVKYldFclQ2WFdscFJKTjdHS25XZVpMRE9CRUlSU3NDS3hKTUtaamxpREN2LTAyc3AtdWdTZlhzZ3kzYmEtMEI5QjVGZ0VVdFN2R0dKUWh2Vm9FelByMUU5N0tXQk5OeU5ZZndqekVNeEJVbHVZVTNUdmFB?oc=5", "source_name": "TradingView", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi\u2011Vec in Ovarian Cancer", "summary": "Genelux Corporation announced the publication of translational findings from its Phase 1b/2 VIRO-15 trial, demonstrating that Olvi-Vec-primed immunochemotherapy promotes immune activation and chemotherapy sensitization in platinum-resistant/refractory ovarian cancer (PRROC) patie", "url": "https://finance.yahoo.com/healthcare/articles/genelux-announces-publication-translational-analysis-120000339.html", "source_name": "Market source", "published_at": "2026-07-02T03:40:25", "published_display": "02 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Two Wall Street analysts have issued bullish sentiments on healthcare companies Genelux Corp. (GNLX) and Abivax SA Sponsored ADR (ABVX). Chad Messer of Lake Street maintained a Buy rating on Genelux with a $16.00 price target, while Sam Slutsky of LifeSci Capital maintained a Buy", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ABVX-Q/pressreleases/3077748/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-07-02T01:40:05", "published_display": "02 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] GENELUX Corp SEC Filing", "summary": "This article announces a Form 144 SEC filing by GENELUX Corp (GNLX) regarding a proposed sale of 12,000 shares of common stock by an insider. The filing indicates these shares, acquired on June 16, 2026, as restricted stock from the Issuer, have an aggregate market value of $34,8", "url": "https://www.stocktitan.net/sec-filings/GNLX/144-genelux-corp-sec-filing-69dd7523fe31.html", "source_name": "Stock Titan", "published_at": "2026-07-01T22:40:14", "published_display": "01 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX Corp SEC Filing (Jul 1, 2026)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxNWWlZR1VGNEJLWTExZ0F6YVdYNlotM0FXWklqTGZXTXZXMDRHQzh6MWl5dFJGWXNnZFBvTHZDMUdUYWdvQ2h6cW9hQlNrbm5zQWdHeXRGeWhKOF92aUJRd0NpVm1tRDN3ajA1dHgwcUJUMVVXY1JRQ29JUTBhbXRFbTl0WVRPX3ZwMG1EV0VvNmlvQ0U?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux says Olvi-Vec may reawaken platinum response in ovarian cancer", "summary": "Genelux announced the publication of translational and clinical findings from its Phase 1b/2 VIRO-15 trial of Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer. The data indicate that Olvi-Vec modulates the tumor microenvironment, activates immune", "url": "https://www.stocktitan.net/news/GNLX/genelux-announces-publication-of-translational-analysis-supporting-aq19b3oa1umr.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:00:25", "published_display": "30 Jun 2026 12:00", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp. Actuals & Estimates (NASDAQ:GNLX)", "summary": "This article provides an analysis of Genelux Corporation (NASDAQ: GNLX) stock, covering its current price, historical performance, analyst forecasts, and key financial metrics. It includes details on revenue, earnings, market capitalization, and volatility, as well as upcoming ea", "url": "https://www.tradingview.com/symbols/NASDAQ-GNLX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:27", "published_display": "26 Jun 2026 10:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Valuation: PE, PB & Fair Value Analysis", "summary": "The article provides a valuation analysis for Genelux Corp (GNLX), noting its current valuation score is 6.10, ranking it in the lower range within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.40, which is significantly below its rece", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-24T22:10:42", "published_display": "24 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Genelux Corp (GNLX), detailing its current risk score of 1.61, which ranks 281 out of 387 in the Biotechnology & Medical Research industry. The company's beta of 0.54 suggests it tends to underperform during market uptrends but experien", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T10:10:16", "published_display": "24 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux elects director and ratifies auditor at annual shareholder meeting By Investing.com", "summary": "Genelux Corporation held its 2026 Annual Meeting of Stockholders, where shareholders elected John Smither as a Class I Director and ratified Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting saw", "url": "https://ng.investing.com/news/stock-market-news/genelux-elects-director-and-ratifies-auditor-at-annual-shareholder-meeting-93CH-2568873", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T22:10:56", "published_display": "22 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Genelux Corp For: 22 June By Investing.com", "summary": "This article from Investing.com is a regulatory filing announcement for Genelux Corp, specifically an 8K form filed for June 22. It is a brief notice and does not contain detailed financial information but indicates a significant event or disclosure by the company. The article al", "url": "https://za.investing.com/news/stock-market-news/form-8k-genelux-corp-for-22-june-93CH-4338693", "source_name": "Investing.com South Africa", "published_at": "2026-06-22T21:10:55", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) 2026 meeting backs director John Smither and auditor", "summary": "Genelux Corporation held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders elected John Smither as a Class I director to serve until the 2029 Annual Meeting. They also ratified Weinberg & Company, P.A. as the independent registered public accounting fir", "url": "https://www.stocktitan.net/sec-filings/GNLX/8-k-genelux-corp-reports-material-event-7661c33273b0.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:57", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Institutional Confidence", "summary": "Genelux Corp (GNLX) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 14.81% quarter-over-quarter, reaching 30.96%. James Simons is the largest inst", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Genelux Corp (GNLX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. As of June 18, 2026, GNLX trades between a resistance of $3.20 and a s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/technical", "source_name": "TradingKey", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (GNLX) Chief Scientific Officer awarded 119,318 RSUs in equity grant", "summary": "GENELUX Corp's Chief Scientific Officer, Yu Yong, received an equity award of 119,318 restricted stock units (RSUs) at no cash cost under the company\u2019s 2022 Equity Incentive Plan. This grant increases his equivalent common stock position to 269,024 shares, with vesting staggered ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-80a86da56b1a.html", "source_name": "Stock Titan", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) director receives RSUs and stock options in new grant", "summary": "Genelux Corp director Mary Mirabelli was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares of common stock at an exercise price of $3.03. These equity awards increase her direct holdings to 102,693 common shares. Both the RSUs and options vest upon ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-5091bc6a677f.html", "source_name": "Stock Titan", "published_at": "2026-06-19T07:40:19", "published_display": "19 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (GNLX) director receives RSU and stock option grants", "summary": "Genelux (GNLX) director Thomas John was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares with an exercise price of $3.03. These equity awards, not open-market trades, were granted on June 16, 2026, and will vest on the earlier of one year from the ", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-a8247091c6a5.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (GNLX) CTO granted 174,841 RSUs under 2022 equity plan", "summary": "GENELUX Corp's Chief Technical Officer, Joseph Cappello, has been granted 174,841 restricted stock units (RSUs) under the company\u2019s 2022 Equity Incentive Plan. This grant, awarded at no purchase price, increases his total directly held common stock and RSU holdings to 329,390 sha", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-1e285d25d5f8.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (NASDAQ: GNLX) grants CEO 730,601 RSUs under 2022 plan", "summary": "Genelux (NASDAQ: GNLX) has granted its President and CEO, Thomas Zindrick, 730,601 restricted stock units (RSUs) under the company\u2019s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant date, with the remainde", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-4b165b623adf.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director James L. Tyree receives RSU and option grants", "summary": "GENELUX (NASDAQ: GNLX) director James L. Tyree was granted 28,409 restricted stock units (RSUs) and stock options for 31,566 shares at an exercise price of $3.03. Following these grants, Tyree directly holds 96,483 shares of common stock. Both the RSUs and options will vest on th", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-d38b711e91a7.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux (NASDAQ: GNLX) grants 233,957 RSUs to General Counsel Eric Groen", "summary": "Genelux Corp (NASDAQ: GNLX) has granted 233,957 restricted stock units (RSUs) to its General Counsel, Eric Groen, as equity compensation under the company\u2019s 2022 Equity Incentive Plan. These RSUs were awarded at no cash cost and will vest 25% on the first anniversary of the grant", "url": "https://www.stocktitan.net/sec-filings/GNLX/form-4-genelux-corp-insider-trading-activity-c3ca697f630c.html", "source_name": "Stock Titan", "published_at": "2026-06-18T22:39:19", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GENELUX (NASDAQ: GNLX) director granted RSUs and options in new equity awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNMzhSdWo1bjR4UnIxR2UtZFpBRXJUN0pLd1lSX3F5a2d3eU5yUlU5X3Z4djJsRWJDZFdpUTYzaGFvZVZ0S21xRXNWQ3NaWlhtamFtUHd0N0VMNEo0TS1UeFd3M2xxU2pxcUJycGNyQ0wtaWs3dXZEdkJuZ3hESHVGZUpuaDNiUFFkUFM3eWRkeWpBTWk1X3pEMVI2dFdRUURUeWo2M3VQaWM2dw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Genelux Corp's (GNLX) dividend and stock split history. It states that Genelux Corp has not distributed any dividends over the past five years and has no recorded stock splits. The financial snapshot shows GNLX's current stock price, market ca", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T07:09:14", "published_display": "18 Jun 2026 07:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Genelux Corp (GNLX), covering business segments, regional revenue, and profit contributions. However, the article states that relevant financial data for these categories have not been disclosed by the compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T06:09:14", "published_display": "18 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Genelux Corp (GNLX) has an earnings forecast score of 8.00, placing it highly within the Biotechnology & Medical Research industry. Analysts have set an average price target of $18.00, with a consensus \"Buy\" rating based on 6 analysts.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T06:41:04", "published_display": "17 Jun 2026 06:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corp (GNLX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Genelux Corp (GNLX) from TradingKey, noting a current financial score of 7.05, which ranks it 159 out of 388 in the Biotechnology & Medical Research industry. The company's financial status is described as stable, but its opera", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-gnlx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-17T06:41:04", "published_display": "17 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxObTdhSlJXM3BhWXRZM1NuWVBvNFZKS09CUkMyLV93TEdVQUdycktzUG5tRnFwUFlabkluMDFsMUpYYzFiQUxPWVdwczhNeVVjN0Rvc2k3VUZuS3NlTmEycHVpMGV1eDhnaEZkQ1JCaHVkcVZnMGd6Q2xzYnVpZV9tVVRLcjZnaWd0NlRhSnRENWIxSzhBQkd5WnRxVXN4dkk?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux head of regulatory Ralph Smalling sells $562 in stock By Investing.com", "summary": "Ralph Smalling, Head of Regulatory at GENELUX Corp, sold 192 shares of company stock worth $562 to cover taxes on restricted stock units. Following the sale, Smalling retains 67,611 shares, and the stock is currently trading at $3.08, significantly below its 52-week high. Investi", "url": "https://m.in.investing.com/news/insider-trading-news/genelux-head-of-regulatory-ralph-smalling-sells-562-in-stock-93CH-5441941?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-05T14:40:41", "published_display": "05 Jun 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux head of regulatory Ralph Smalling sells $562 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMHR3MXBVUzRrc3FPT2JxVmZNUi1zUGthcHVDLUdwblNSajQxa1d6UmdCVG5zWFBOMzdyQUtmaG1fMzZocWxMZ2VlUHZhdGhRczhMbjhvX3QtQUE4eHNTVjZBaWhoQWZNRzNyeHQzcHFUallDVVF6Rkp6VFJna21iMC0yM204SlZHR2tySkZ2Z2RGUGlibGRtdnJudHI2NmdtSlQ1aHJhemFjMWxNWklqa2dGYzdZaFowWFp3NTkzOG5qS3c?oc=5", "source_name": "Investing.com", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux director Thomas John sold $29,801 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQc3p2b2FqZ0pySXlxb0xhaFpxSFJ2QnFpekpSVG1rWVlBMFdJYmVwMDVDSmFvX1JWLVJweFBscG5LeWZPa29NempZVVNUUGZxWThtc2gwSEdRbkY0clNrNy1CM0IxOGN6RldkOU9kR2tLeGZKbjNJSXZvcEdZMjVSRmo5dmRnLU5PYVdCMHdvRjZyek9HOVg1NFBzQUF3ajVlQ202OGxKM09faUdxNnkwMzVhal8wbHZmbFpTdm5n?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux CSO Yu Yong sells $1,798 of common stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPSEl6V2pmSThmWTZqczg2SzFkSFNTUjRrYVhoQk5hSFlILW1DMEVjOFIwNVFxOVAtTmpGall6dUFSaW4ycFRmdWs5NklVc1BVSEY0RDFEX00xLVFURjFKV2g3bXdJbGt0bVY4X1BQQ1JFcHlpVGgzWFBCQ09RTHQ0Ti1nYjJ5cVdRVWZVSGZYTHlfZy1rVTgzdE1QRmhLZEtVbTRrZGhva2dlOXZvNmFjWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux president and CEO Zindrick Thomas sells $8,225 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNRkhZQ0JtbU5vV3ZPOVBnXzBaWXI5eEs0blJxRXI4MndNUTQ1ZldWdTFnYWxPSUI3U1YzcFFEY01PcmcwR0tjWGlscF9JZXVfQ00taFlTMkl1eTg1a1ZlejZYbl95MWQteUNpZ2kzNHo0VFRWU1I4bGFUMVp3XzRESGhhLVBjTjF6cG5kTmRVUVROWDdiblBHTzFKOFpUSzJPLU5rVWlXOVVxWE0tWncwdDBXU1A2VTE2QXpMNTQ5bXkxbGFh?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux CTO Joseph Cappello sells $1,799 in company stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOTjFITl9Bb1VId1RfZmwwbWVObnZjX0U3c0pHSUJYdzBtNXZmLUF6STlrU2lkRWJGc2N0YXpoU0Q3MWZxOWtyQ1ZxVFluUFFvemdIMldZLUpEQjJZZTAyZVFsWUxFV3BYNEliNGhnXzdLbk5XUTdWSjB1WE1qRWVXZFJhajJMdVVOaHNaNzdXWjFab1BQZU9sRFJ3Z1RTRkxlSG42dlhCUTNtUnEtX0hPRWk1c214Nmx2cGEwaw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxPYVBjRlR4bzJVTEZIOG5ZcWJhdFhRdElYQURuVWJqZ1NuWWNxaGhod3A3TTNBNHNHbVZPeS03SWVCYVhWYTU1dkU5djFUUTdWbUtrZVFDLTIxOWd5emhXOVhIaU4xcFJLMHprX1pLeUt6bTktV0x5T3lGel83V0p1LVc4WXNHd25fWWdoMjZkMHpwMHJzMFA4MmQxdW85RDZ6NGpRbWdpSzhLbFV0cVFDR2htbzZPRmN6VUNpRTNQMWYzMlZsRU5KYVd2TWZra1kyQnZfUGNBTlJhMld1eE0yQk40V1ktdXBweWhseWxyLTY0X1U?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSGpqV09Qc0RwZVU4cm1RODdrSUJFdWNYYmw5ZVNMTmhDRVhCTm15aTZSajhRckF6R194Q1hqTjZKQXJlbmJDMC1XT21TRDVfZ2xidWd4NzdxVE5oV1RURFhRMkFqajJUTnRQWm1GeUp6V1VJMzdKTzh0OGczWkp4M1VzdmR5Um43dVlSVnF2Tk1jTU9peTJvdkpHQUNjNlpSSmp0UEZwSWwzcnZZSUtJbVdiNnREOGtpaThF?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Molina Healthcare Stock Craters. Why Its Earnings Outlook Is So Bleak.", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPX1JJd3MzSGZ4Tl9ZWUduMTAtSUNrdVJDZFE2YnVGZzhvTUt6OXZNcHFPSG1LaWJ5a3NnQV9VeEZtYlNMVVlvaXZOanJreFVOcTd0U0phaUdhQUxjbFFwazc5S0ZYY1hWN25WalhXUGVQZEh5UnB3UDVWSzRoS3VsWnk5ek11X0k?oc=5", "source_name": "Barron's", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNYlk5WnpEUy1WdDhnWlZ0LUlISTZzVG94cVM5WWNGNU8ycVBLNFpZQlZMYUFlcFpFb3h1NmhCcEJoTEVJT1REYmtsSlJYVGkzQ3NTcWF2a1J0V2plX2pnaUNCd1dlZ1BFaEROOWVscGtERXVOdzA2dDZhV1hpQzJ3QjBYSkxzd2pUak12X1UzTjZiT3kxai1MemhwYkk5dGF6SUVKNUJQS2IxaXVNcUZ2X3ZOR1RFdnVMRGVTd2xQQUpVR3ZtQXNmZ3FxQnowZnhFanZwellrb3hfaVVLeGJacGw5anZUTm9JQlB6dVk0UmJRZERpQlZWMUlaU1dHTVU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-08T08:00:00+00:00", "published_display": "08 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux Corporation Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxQNE5uLTBkS3VDeDBuSlpGai1EMTVoUW52UkN2d0pMcnFfMjBXQ3g0NEVjQl96d29TOURwTVpvdjBDQ1Fsdy0wdl9iZmdvcE92VmRmNXVYY2VybVdRM1VaT3M1NFVDWFBPbV82Z0NTZFlfeVpSRUtCbGVlZmdvRWgyVDFiSWVtOVhpQUdYa29CV3lUcVlIekE?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux stock falls after announcing proposed public offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOM1RZZ25wNFI2THE0ckRueGtUVEdhWHFScUFhaG01Yk9QOUNIdWQ1M2d6OV9wYl91VjBzeWFhQlJma0QzQzYtNm9ZNW9zVzRVTnBmV2plTDJITkVwbkZoYlduOVlNMy1RWFNJajc1UEtWZWc0MWVubVlSa21nWVpsQWZBem9jMFdkS2pqZXd6em5sWk9HSktMZ2p1QzlQeWFPOWFnRFU0SFJxY0FlX2FvbWI2ZWxjN0RwWmx4aE5tOWI?oc=5", "source_name": "Investing.com", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genelux: Oncolytic Virus Player Near Phase 3 Finish Line, But Correction Likely (GNLX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRGZ3QkhBRmg0S0wwZEtvbkZ3bE1UQ21BbWxicWM0RFZOaXF3OFZZQjFxTjlGS3BNN2dBOHF5a2FnbHhkQktqR3Z3Rmh0WlBMNjN3LTZod1ExZGRLczR2OHZqMEloY1MwRGdMUUxtbjRxeUNidUs4X2UxcUhHRHI2dWhzWHVpOXF5TEpkMlVaUFpCSVNDaWtHb1FmeGtJVlpCYV9FUGNPOGduc2JjV0JSaF9OUF94dw?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$GNLX stock is down 30% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOamxvNXFKb1g5RmdJd2pXSkhPaXVOYmxjbTFLUWlYbFN2T2xFU1BzSjJweXdGUHlWRjQwdVlVd3ZBZElKejFnQUJRZXEyRmlkUGlrRk9GZnU0b3VXZGRYekM1TWo1c3cwSXBQYVl5OHJWMk9TT1lqSnYtSEdWdUc1VUZUMjFoWXBIMWUxYlg0eGVoLXZFc2RTSlJGWnZMb2hWbXgw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 83, "total_relevant": 62, "sentiment_summary": {"positive": 13, "negative": 6, "neutral": 43, "score": 53, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 18.85, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 9.7, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 13, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 2.87, "latest_week": "2026-07-17", "one_week_move": -5.3, "four_week_move": -3.2, "twelve_week_move": 13.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.744034, "market_dynamics_buy_signal": false, "relative_strength": -29.417538, "fair_value_gap": -52.2, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.5987, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.3% over one week, -3.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 10}, {"label": "TradingKey", "count": 8}, {"label": "Investing.com", "count": 6}, {"label": "TradingView", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "GlobeNewswire", "count": 2}, {"label": "TIKR.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 3}, {"label": "Balance sheet", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.3% over one week, -3.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Teleflex Incorporated (TFX) Stock Analysis: Unpacking a 32.3% Revenue Growth in the Healthcare Sector"}], "updated_at": "2026-07-22T05:12:47.737100+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}